Mitogen-induced blastogenesis and receptor mobility inhibition by breast cancer serum with elevated orosomucoid (α1-acid glycoprotein) levels

D. A. Cheresh, J. A. Distasio, C. L. Vogel, D. M. Lopez

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Sera from cancer patients have been shown to suppress normal lymphoid cell responsiveness in vitro. In the present study, sera from breast cancer patients were demonstrated to be inhibitory to the concanavalin A (Con A)-, Proteus vulgaris-derived phytohemagglutinin-, and pokeweed mitogen-induced blastogenic responses of normal lymphoid cells. Orosomucoid (OR) (α1-acid glycoprotein), an acutephase reactant, was elevated in these sera, and a positive correlation existed between the OR level in the sera and its immunosuppressive capacity. When normal lymphoid cells were reacted in fluorescein isothiocyanate-labeled Con A, cells that had been preincubated in breast cancer sera known to contain an elevated level of OR showed a significant decrease in Con A receptor mobility as compared to the receptor mobility of the same lymphoid cells preincubated in normal sera. Thus a component(s) from the sera of breast cancer patients had the capacity to inhibit lymphocyte activation. This inhibition might have resulted from an interaction of OR with the cell membrane.

Original languageEnglish (US)
Pages (from-to)779-783
Number of pages5
JournalJournal of the National Cancer Institute
Volume68
Issue number5
StatePublished - Jan 1 1982

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Mitogen-induced blastogenesis and receptor mobility inhibition by breast cancer serum with elevated orosomucoid (α<sub>1</sub>-acid glycoprotein) levels'. Together they form a unique fingerprint.

Cite this